Novo CSO: Oxford center will create waves to Denmark

The head of Novo Nordisk’s R&D work admits the company has reached a certain level of maturity in its own research in Denmark and is now “highly dependent” on external basic research. That is the reason for a new GBP 115 investment in the University of Oxford.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Reuters: Kinesere vil købe J&J's diabetesforretning

Amerikanske Johnson & Johnson kan være på vej til at sælge sin forretning for diabetesudstyr for godt 24 mia. kr., efter flere kinesiske aktører ifølge Reuters har vist interesse i at overtage forretningsdelen.

Related articles